Innate Pharma SA
PAR:IPH
Innate Pharma SA
Interest Expense
Innate Pharma SA
Interest Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Innate Pharma SA
PAR:IPH
|
Interest Expense
€495k
|
CAGR 3-Years
13%
|
CAGR 5-Years
8%
|
CAGR 10-Years
21%
|
|
|
Valneva SE
PAR:VLA
|
Interest Expense
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Interest Expense
€3.5m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
45%
|
|
|
Inventiva SA
PAR:IVA
|
Interest Expense
€16.7m
|
CAGR 3-Years
330%
|
CAGR 5-Years
301%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Interest Expense
$346k
|
CAGR 3-Years
46%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
Abivax SA
PAR:ABVX
|
Interest Expense
€18.8m
|
CAGR 3-Years
123%
|
CAGR 5-Years
81%
|
CAGR 10-Years
N/A
|
|
Innate Pharma SA
Glance View
Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. The company is headquartered in Marseille, Paca and currently employs 215 full-time employees. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The firm works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.
See Also
What is Innate Pharma SA's Interest Expense?
Interest Expense
495k
EUR
Based on the financial report for Jun 30, 2025, Innate Pharma SA's Interest Expense amounts to 495k EUR.
What is Innate Pharma SA's Interest Expense growth rate?
Interest Expense CAGR 10Y
21%
Over the last year, the Interest Expense growth was -20%. The average annual Interest Expense growth rates for Innate Pharma SA have been 13% over the past three years , 8% over the past five years , and 21% over the past ten years .
